| 1. |
- Gandolfi, D., et al.
(författare)
-
Kepler-423b: a half-Jupiter mass planet transiting a very old solar-like star
- 2015
-
Ingår i: Astronomy and Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 576
-
Tidskriftsartikel (refereegranskat)abstract
- We report the spectroscopic confirmation of the Kepler object of interest KOI-183.01 (Kepler-423b), a half-Jupiter mass planet transiting an old solar-like star every 2.7 days. Our analysis is the first to combine the full Kepler photometry (quarters 1 17) with high-precision radial velocity measurements taken with the FIES spectrograph at the Nordic Optical Telescope. We simultaneously modelled the photometric and spectroscopic data-sets using Bayesian approach coupled with Markov chain Monte Carlo sampling. We found that the Kepler pre-search data conditioned light curve of Kepler-423 exhibits quarter-to-quarter systematic variations of the transit depth, with a peak-to-peak amplitude of similar to 4.3% and seasonal trends reoccurring every four quarters. We attributed these systematics to an incorrect assessment of the quarterly variation of the crowding metric. The host star Kepler-423 is a G4 dwarf with M-* = 0.85 +/- 0.04 M-circle dot, R-* = 0.95 +/- 0.04 R-circle dot, T-eff = 5560 +/- 80 K, [M/H] = -0.10 +/- 0.05 dex, and with an age of 11 +/- 2 Gyr. The planet Kepler-423b has a mass of M-p = 0.595 +/- 0.081 M-Jup and a radius of R-p = 1.192 +/- 0.052 R-Jup, yielding a planetary bulk density of rho(p) = 0.459 +/- 0.083 g cm(-3). The radius of Kepler-423b is consistent with both theoretical models for irradiated coreless giant planets and expectations based on empirical laws. The inclination of the stellar spin axis suggests that the system is aligned along the line of sight. We detected a tentative secondary eclipse of the planet at a 2 sigma confidence level (Delta F-ec = 14.2 +/- 6.6 ppm) and found that the orbit might have a small non-zero eccentricity of 0.019(-0.014)(+0.028) . With a Bond albedo of A(B) = 0.037 +/- 0.019, Kepler-423b is one of the gas-giant planets with the lowest albedo known so far.
|
|
| 2. |
- Sangchooli, Arshiya, et al.
(författare)
-
Parameter Space and Potential for Biomarker Development in 25 Years of fMRI Drug Cue Reactivity
- 2024
-
Ingår i: JAMA psychiatry. - : AMER MEDICAL ASSOC. - 2168-6238 .- 2168-622X.
-
Forskningsöversikt (refereegranskat)abstract
- Importance In the last 25 years, functional magnetic resonance imaging drug cue reactivity (FDCR) studies have characterized some core aspects in the neurobiology of drug addiction. However, no FDCR-derived biomarkers have been approved for treatment development or clinical adoption. Traversing this translational gap requires a systematic assessment of the FDCR literature evidence, its heterogeneity, and an evaluation of possible clinical uses of FDCR-derived biomarkers. Objective To summarize the state of the field of FDCR, assess their potential for biomarker development, and outline a clear process for biomarker qualification to guide future research and validation efforts. Evidence Review The PubMed and Medline databases were searched for every original FDCR investigation published from database inception until December 2022. Collected data covered study design, participant characteristics, FDCR task design, and whether each study provided evidence that might potentially help develop susceptibility, diagnostic, response, prognostic, predictive, or severity biomarkers for 1 or more addictive disorders. Findings There were 415 FDCR studies published between 1998 and 2022. Most focused on nicotine (122 [29.6%]), alcohol (120 [29.2%]), or cocaine (46 [11.1%]), and most used visual cues (354 [85.3%]). Together, these studies recruited 19 311 participants, including 13 812 individuals with past or current substance use disorders. Most studies could potentially support biomarker development, including diagnostic (143 [32.7%]), treatment response (141 [32.3%]), severity (84 [19.2%]), prognostic (30 [6.9%]), predictive (25 [5.7%]), monitoring (12 [2.7%]), and susceptibility (2 [0.5%]) biomarkers. A total of 155 interventional studies used FDCR, mostly to investigate pharmacological (67 [43.2%]) or cognitive/behavioral (51 [32.9%]) interventions; 141 studies used FDCR as a response measure, of which 125 (88.7%) reported significant interventional FDCR alterations; and 25 studies used FDCR as an intervention outcome predictor, with 24 (96%) finding significant associations between FDCR markers and treatment outcomes. Conclusions and Relevance Based on this systematic review and the proposed biomarker development framework, there is a pathway for the development and regulatory qualification of FDCR-based biomarkers of addiction and recovery. Further validation could support the use of FDCR-derived measures, potentially accelerating treatment development and improving diagnostic, prognostic, and predictive clinical judgments.
|
|
